Core Insights - Cloudtop New Horizon's core product, Nefikang®, has received full approval from Taiwan's drug regulatory authority, removing previous conditions related to clinical efficacy proof, thus solidifying its position as a first-line treatment for IgA nephropathy in Asia [1][3] - The product's production capacity upgrade has been approved by the NMPA, allowing for a more efficient response to the growing clinical demand in China and Asia [1][2] - Nefikang® is projected to achieve sales of 1 billion yuan in its first full year post-launch, highlighting its market potential [1] Product Approval and Market Position - Nefikang® is the first non-oncology drug to be included in China's breakthrough therapy category, addressing the treatment gap for IgA nephropathy [2][3] - The drug has been fully approved in all authorized regions, including major markets like the US, EU, and several Asian countries, enhancing its commercial viability [4] - The drug's unique mechanism of action targets gut mucosal immunity, effectively controlling proteinuria and protecting kidney function, establishing it as a cornerstone treatment [3][4] Clinical Demand and Commercial Strategy - IgA nephropathy is prevalent in Asia, with over 5 million patients in China and an annual increase of over 100,000 new cases, indicating a significant unmet clinical need [2][4] - Cloudtop New Horizon has established an efficient commercialization system, covering over 80% of potential hospitals in mainland China, benefiting more than 20,000 patients [4] - Securities firms predict peak sales for Nefikang® could reach 5 billion yuan, indicating its potential as a major product in the nephrology market [4]

Core Viewpoint - CloudTop New Drug (1952.HK) has received full approval for its core nephrology product, Nefikang, in Taiwan, removing previous conditions and solidifying its position as a first-line treatment for IgA nephropathy in Asia [1][2] Group 1: Product Approval and Market Potential - Nefikang is now fully approved in all authorized regions, enhancing its status as a cornerstone treatment for IgA nephropathy [1] - The product's production capacity upgrade has been approved by the NMPA, allowing for a more efficient response to the growing clinical demand in China and Asia [1][2] - The market potential is significant, with expectations of achieving sales of 1 billion yuan in its first full year post-launch [1] Group 2: Clinical Significance and Treatment Landscape - IgA nephropathy is the most common primary glomerular disease globally, with a higher risk of progression to end-stage renal disease in Asian populations [2] - Nefikang fills a critical gap in the treatment landscape, being the first drug approved for targeted therapy in IgA nephropathy, addressing previous limitations of existing treatments [2][3] - Clinical studies show that Nefikang can reduce kidney function decline by up to 66% in the Chinese population, significantly delaying the need for dialysis or kidney transplantation [3] Group 3: Commercialization and Market Strategy - Nefikang is the first IgA nephropathy treatment to receive full approval from multiple regulatory agencies, including NMPA, FDA, and EMA, establishing a strong foundation for commercialization [4] - The drug has already reached over 80% of potential hospitals in mainland China, benefiting more than 20,000 patients, demonstrating the company's market penetration capabilities [4] - Sales peak forecasts suggest that Nefikang could reach 5 billion yuan, indicating its potential as a major product in the nephrology market [4]

Core Insights - The majority of ordinary stock funds in China have performed well in the first seven months of the year, with 92% of the 983 funds showing positive returns [1] - The top-performing fund, Huaan Medical Biotechnology, achieved a remarkable increase of over 105% [1] - The strong performance of these funds is largely attributed to their heavy investments in the pharmaceutical sector, with several stocks experiencing significant gains [2][3] Fund Performance - Huaan Medical Biotechnology Fund A and C led the performance with increases of 105.40% and 104.88% respectively, heavily investing in companies like Innovent Biologics and Stone Pharma [1] - Other notable funds include Jiashi Mutual Selection and Fortune Medical Innovation, which saw increases of 97.28% and 96.67% respectively, also focusing on pharmaceutical stocks [2] - Funds with over 80% growth include Ping An Medical Selected Stocks and Penghua Medical Technology Stocks, indicating a strong trend in the healthcare investment space [3] Underperforming Funds - Only seven funds experienced declines exceeding 10%, primarily in sectors like consumer goods, new energy, and technology [4] - The Minsheng Plus Silver Preferred Stock Fund saw a decline of 13.06%, with major holdings in companies like CATL and BYD [4] - Other funds with significant declines include Changxin Consumer Selected Quantitative Stocks and Beixin Ruifeng Preferred Growth, both heavily invested in the liquor sector [5]

Core Insights - The healthcare ETF, Taikang (159760), has shown a slight increase of 0.46%, tracking the National Public Health and Healthcare Index (980016), which rose by 0.48% [1] - A new pricing mechanism for newly launched drugs has been established by the National Healthcare Security Administration, allowing high-level innovative drugs a five-year price stability period, which is expected to reverse the trend of price drops upon market entry [1] - Innovative drugs like Zebutinib from BeiGene and the dual-antibody drug from Baillie Tianheng are anticipated to drive significant revenue growth in the coming years [1][2] Industry Developments - The index constituents are experiencing a technological breakthrough, with companies like Kangfang Bio and Eli Lilly making significant advancements in drug development [2] - The AI+mRNA platform developed by CloudTop has achieved full-chain coverage from antigen design to industrial production, indicating a shift in innovative drug development paradigms [3] - The index includes companies that are directly benefiting from healthcare payment reforms and supportive policies for innovative drugs, with over 80% of the constituents poised to gain from these changes [4] Financial Performance - As of June 30, 2025, the top ten weighted stocks in the National Public Health and Healthcare Index accounted for 51.67% of the index, with companies like WuXi AppTec and Hengrui Medicine leading the way [5] - Hengrui Medicine's R&D investment ratio reached 28% in the first half of 2025, with a 50% year-on-year increase in the number of new drug approvals, indicating strong growth potential [4] Market Outlook - The healthcare ETF is expected to continue leading in the structural market of the healthcare industry, driven by the expansion of commercial insurance innovative drug catalogs and accelerated approvals for AI medical devices [4] - The index reflects the performance of listed companies in the public health and healthcare sector, focusing on prevention, testing, and treatment areas with significant potential for AI technology applications [4]

Summary of Key Points from the Conference Call Company Overview - **Company**: 云顶医药 (Cloudtop Pharmaceuticals) - **Industry**: Biopharmaceuticals, specifically focusing on anti-infective and renal disease treatments Core Insights and Arguments - **Market Demand**: The demand for the drug 依拉环素 (Ilaris) is strong, with projected sales reaching 1 billion yuan in 2025, indicating a growing hospital market [2][3] - **Product Pipeline**: The company is expanding its product line with new anti-infective products such as 坦尼彭巴坦 (Tanecomartin) and F206, further solidifying its position in the anti-infective sector [2][3] - **Self-developed Products**: BDK ever 001 has shown impressive results in clinical trials, being recognized as a best-in-class product. The mRNA tumor vaccine platform has entered patient enrollment, with encouraging preliminary data [2][4][5] - **Financial Performance**: The drug 耐福康 (Nafamostat) is expected to achieve sales of 1 billion yuan in 2025, with a potential peak sales target of 4 to 5 billion yuan in the long term [2][18] - **Clinical Data**: For the drug Alpha 001, used in treating membranous nephropathy, the complete remission rates were 76.9% for the low-dose group and 81.8% for the high-dose group, indicating leading efficacy in its class [2][21] Management and Structure - **Stable Shareholding**: The company is controlled by CBC, with the introduction of long-term international investors, ensuring a stable shareholding structure [2][6] - **Experienced Management**: The management team, led by CEO 罗总 and CFO 何总, has extensive experience in large multinational companies, which aids in effective commercialization and strategic planning [2][7] Future Development Goals - **Revenue Target**: The company aims to achieve a revenue target of 10 billion yuan by 2030 through expanding existing product sales and developing new indications for I8-001 and the mRNA platform [2][8] - **Market Positioning**: The company seeks to consolidate its market position and expand its business scale in the coming years [2][9] Additional Important Insights - **IgA Nephropathy Treatment**: The drug 耐赋康 has shown strong performance in treating IgA nephropathy, with a significant market opportunity given the prevalence of the disease in China [2][14][18] - **Competitive Landscape**: Other drugs for IgA nephropathy are in development, but 云顶医药 is expected to maintain a leading position for the next two to three years [2][19] - **mRNA and CAR-T Developments**: The company is advancing its mRNA technology platform and in vivo CAR-T therapy, with significant investments in these areas indicating strong future potential [2][22][23] Conclusion - **Investment Opportunities**: The company presents multiple investment opportunities through its robust product pipeline, strong market demand, and experienced management team, making it a noteworthy player in the biopharmaceutical industry [2][25]

Group 1 - The core viewpoint highlights the strong performance of the innovative drug ETF (560900), which rose over 1% on August 5, 2025, with significant trading volume and notable increases in constituent stocks [1] - The innovative drug ETF (560900) experienced a weekly scale growth of 219.80 million yuan, ranking first among comparable funds, and a substantial increase of 4 million shares [1] - Recent net inflows into the innovative drug ETF (560900) totaled 973,700 yuan, with a total of 11.04 million yuan in net inflows over the past five trading days [1] Group 2 - Century Securities noted a resurgence in innovative drug licensing collaborations, including a significant $500 million upfront payment deal between Hengrui Medicine and GlaxoSmithKline, covering a potential total of $12 billion [2] - The innovative drug asset landscape is diversifying beyond oncology to include respiratory, metabolic, and immune therapies, with collaborations involving multinational corporations, new companies, state-owned enterprises, and biotech firms [2] - The innovative drug ETF (560900) closely tracks the CSI Innovative Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug research and development [2] Group 3 - Morgan Asset Management is integrating its "Global Vision Investment Technology" product line to assist investors in identifying quality technology companies globally, capitalizing on the new wave of technological advancements driven by AI [3]

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (74.76%), Gree Power (70.14%), and China Shenhua (67.05%) [1] - The largest increases in holdings over the last five trading days were seen in the following companies: Yingfu Fund (+2.967 billion), Li Auto-W (+2.821 billion), and Hang Seng China Enterprises (+2.531 billion) [1] - The largest decreases in holdings over the last five trading days were recorded for Pop Mart (-807 million), China Mobile (-777 million), and Geely Automobile (-630 million) [2] Group 1: Hong Kong Stock Connect Holding Ratios - China Telecom (00728) holds 10.377 billion shares with a holding ratio of 74.76% [1] - Gree Power (01330) has 284 million shares and a holding ratio of 70.14% [1] - China Shenhua (01088) possesses 2.265 billion shares with a holding ratio of 67.05% [1] Group 2: Recent Increases in Holdings - Yingfu Fund (02800) saw an increase of +2.967 billion with a change of +11.772 million shares [1] - Li Auto-W (02015) increased by +2.821 billion with a change of +2.787 million shares [1] - Hang Seng China Enterprises (02828) rose by +2.531 billion with a change of +2.782 million shares [1] Group 3: Recent Decreases in Holdings - Pop Mart (09992) experienced a decrease of -807 million with a change of -321.66 thousand shares [2] - China Mobile (00941) saw a reduction of -777 million with a change of -908.28 thousand shares [2] - Geely Automobile (00175) decreased by -630 million with a change of -3,480.90 thousand shares [2]

Group 1 - The top three stocks with net inflows of southbound funds are Yingfu Fund (02800) with 2.858 billion, Hang Seng China Enterprises (02828) with 2.255 billion, and Meituan-W (03690) with 1.397 billion [1][2] - The top three stocks with net outflows of southbound funds are Pop Mart (09992) with -0.382 billion, Ping An of China (02318) with -0.360 billion, and Laopu Gold (06181) with -0.345 billion [1][2] - In terms of net inflow ratio, the top three are Hopson Development Holdings (00754) at 70.43%, K Wah International Holdings (00173) at 64.10%, and Qingdao Port International (06198) at 61.26% [1][2] Group 2 - The top three stocks with the highest net outflow ratios are Gawei Electronics (01415) at -60.55%, Bank of China Aviation Leasing (02588) at -46.75%, and GX Hengsheng Technology (02837) at -43.69% [1][3] - The top ten stocks with the highest net inflows include Kuaishou-W (01024) with 1.391 billion and Alibaba-W (09988) with 1.040 billion [2] - The top ten stocks with the highest net outflows also include CICC (03908) with -0.333 billion and Kangfang Biologics (09926) with -0.263 billion [2]

Core Viewpoint - Cloudtop New Horizon Pharmaceutical Technology Co., Ltd. has received approval from the National Medical Products Administration (NMPA) for the expansion of production for its drug, Nefukang (Budenoside Enteric-Coated Capsules), which is the first and only approved treatment for IgA nephropathy in China, the US, and Europe, aiming to meet the growing clinical demand in China and Asia [2] Company Summary - Nefukang was approved in November 2023 through a priority review process, becoming the first approved drug for the cause of IgA nephropathy in China, filling a significant treatment gap [2] - The projected annual sales for Nefukang in 2024 are expected to reach 354 million yuan [2] - In November 2024, Nefukang will be included in the national medical insurance catalog, and by May 2025, it will receive full approval from NMPA, removing previous restrictions on proteinuria levels, thus expanding the potential patient population by three times [2] - Currently, Nefukang has covered over 80% of potential hospitals in China, benefiting more than 20,000 patients, indicating a strong demand for increased production capacity to meet patient needs [2] Industry Summary - China has the highest incidence rate of primary glomerular diseases globally, highlighting the urgent need for effective treatments like Nefukang [2] - Cloudtop New Horizon is also developing a next-generation covalent reversible BTK inhibitor, EVER001, which aims to address global clinical gaps in diseases such as primary membranous nephropathy (pMN), minimal change disease (MCD), and focal segmental glomerulosclerosis (FSGS) [2] - The company is advancing clinical research for a Gd-IgA1 diagnostic reagent, expected to be approved for market by 2026, which may replace kidney biopsy as an auxiliary diagnostic tool [2]

Group 1 - The Hang Seng Healthcare Index (HSHCI) increased by 0.37% as of August 4, 2025, with notable gains from companies such as Cloudmed (01952) up 8.70% and Crystal Technology (02228) up 7.19% [3] - The Hang Seng Healthcare ETF (513060) experienced a decline of 0.59%, with a latest price of 0.67 yuan, but showed a 3.36% increase over the past week as of August 1, 2025 [3] - The liquidity of the Hang Seng Healthcare ETF was active, with a turnover rate of 25.84% and a trading volume of 1.911 billion yuan [3] Group 2 - Global advancements in the weight loss sector are gaining attention, with multinational pharmaceutical companies like AbbVie, Roche, and Eli Lilly accelerating their amylin-related pipelines [4] - Eli Lilly's Eloralintide showed promising weight loss results in Phase 1 clinical trials, achieving a maximum weight loss of 11.3% over 12 weeks with a low incidence of gastrointestinal adverse effects [4] - The amylin molecules in development have half-lives ranging from 10 to 18 days, potentially allowing for monthly dosing and improving patient compliance [4] Group 3 - The latest financing buy-in amount for the Hang Seng Healthcare ETF reached 164 million yuan, with a financing balance of 209 million yuan [5] - Over the past two years, the net value of the Hang Seng Healthcare ETF has increased by 28.35%, with a maximum single-month return of 28.34% since inception [5] - The ETF has a Sharpe ratio of 2.39 for the past year, indicating strong risk-adjusted returns [5] Group 4 - The management fee for the Hang Seng Healthcare ETF is 0.50%, and the custody fee is 0.15% [6] - The ETF's tracking error over the past year is 0.060%, the highest tracking precision among comparable funds [6] - The latest P/E ratio for the Hang Seng Healthcare Index is 31.37, indicating it is at a historical low compared to the past three years [6] Group 5 - The top ten weighted stocks in the Hang Seng Healthcare Index account for 62.03% of the index, including companies like BeiGene (06160) and WuXi Biologics (02269) [6]